Study of JS001 in Participants With Advanced Solid Tumors
NCT02857166
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumors
Interventions
BIOLOGICAL:
humanized anti-PD-1 monoclonal antibody toripalimab
Sponsor
Shanghai Junshi Bioscience Co., Ltd.